Karen Costello

Eli Lilly

Thomas Fuchs

Eli Lilly has appointed Thomas Fuchs as chief artificial intelligence (AI) officer. Fuchs joins the company after serving as dean and inaugural department chair for AI and human health at Mount Sinai. He was also director of the Hasso Plattner Institute for Digital Health and Barbara T Murphy professor for AI and computational pathology at the Icahn School of Medicine.

CMT Research Foundation

Laura MacNeill

The CMT Research Foundation has appointed Laura MacNeill as chief executive officer. MacNeill brings over 15 years of experience as a senior non-profit executive to her latest position. She most recently served as chief executive officer of Global Lyme Alliance, and previously held executive director roles at the Leukemia & Lymphoma Society.

Secarna Pharmaceuticals

Konstantin Petropoulos

Secarna Pharmaceuticals has appointed Konstantin Petropoulos as chief executive officer. Petropoulos takes on the role after serving as the company’s chief business officer. He was previously chief executive officer of AMW and held senior management positions in business development and commercialisation at companies including Bayer and Leukocare.

Genascence

Jeymi Tambiah

Genascence has appointed Jeymi Tambiah as chief medical officer. Tambiah is a physician-scientist with more than 15 years of biopharma industry experience. He was most recently senior vice president of clinical development and external innovation at Biosplice Therapeutics. Previously, Jeymi worked for UCB Pharma in various roles within medical affairs.

Sciensus

Christian Tucat

Sciensus has appointed Christian Tucat as chief executive officer. Tucat has spent 25 years in the life sciences sector. He takes on the role after serving in multiple senior roles at Syneos Health, including as chief business officer, president of Syneos One and president of real-world evidence solutions. He has also held positions at SharpView Ophthalmology and INC Research.

PLL Therapeutics

Souad Kechairi

PLL Therapeutics has appointed Souad Kechairi as chief medical officer. Kechairi has two decades of European and wider global clinical trial research experience and joins PLL from Syneos Health, where she held advisory and international management roles of increasing responsibility, including serving as executive medical director of the company’s central nervous system unit.

MitoRx Therapeutics

David Holbrook

MitoRx Therapeutics has appointed David Holbrook as an independent non-executive director. Holbrook brings a wealth of experience to the MitoRx board, with his background spanning global business development at companies such as GSK and Roche. He is also a physician and has held a variety of roles at LifeArc, MTI and Cambridge Enterprise.

Eligo Bioscience

Bobby Gaspar

Eligo Bioscience has appointed Bobby Gaspar as chair of its board of directors. Gaspar brings more than three decades of experience in developing gene therapies to the role. He is currently chief executive officer of Orchard Therapeutics, which he co-founded. Gaspar is also an honorary professor of paediatrics and immunology at University College London.